Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023

OBJECTIVE: Over the past few decades, the development of anti-cancer drugs in China has made outstanding achievements based on the support of national policies. To assess the progress of non-small cell lung cancer (NSCLC) drugs, we conducted a statistical analysis of clinical trials of drugs targeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Wanying, Yu, Haiyan, Song, Li, Wang, Jian, Niu, Shuyu, Zang, Guojie, Liang, Mingjie, Liu, Jinwei, Na, Risu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687557/
https://www.ncbi.nlm.nih.gov/pubmed/38034540
http://dx.doi.org/10.3389/fmed.2023.1239351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687557/
https://www.ncbi.nlm.nih.gov/pubmed/38034540
http://dx.doi.org/10.3389/fmed.2023.1239351

Ejemplares similares